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Familial platelet disorder with predisposition to acute 
myelogenous leukemia (FPD/AML) is an autosomal 
dominant disorder caused by germline heterozygous 
mutations in the hematopoietic transcription factor 
RUNX1. Thirty-six pedigrees have been reported to 
date. Although rare, the frequency of this disorder has 
been probably underestimated and it is now being 
increasingly recognized due to enhanced awareness. 
FPD/AML represents one of the few identified 
genetic disorders underlying pure familial 
myelodysplastic syndrome (MDS)/AML cases and 
represents a useful model to unravel the role of 
RUNX1 in leukemogenesis. 
Clinics 
Note 
FPD/AML is characterized by inherited 
thrombocytopenia, platelet function defect and a 
lifelong risk of development of hematologic 
malignancies (Song et al., 1999). Thrombocytopenia 
is usually mild to moderate and is characterized by 
normal platelet size. Bleeding tends to be more severe 
than expected according to the degree of 
thrombocytopenia due to the presence of associated 
platelet dysfunction and may result in a significant 
bleeding diathesis. Platelet aggregation is abnormal in 
response to several platelet agonists and an aspirin-
like defect has been described. Although 
thrombocytopenia is almost always present, normal 
or low-normal platelet counts have been reported in 
some patients. Similarly, although platelet 
dysfunction represents a very frequent feature of this 
disorder, at present, it is unknown whether all 
individuals with germline RUNX1 mutation display 
this abnormality. Furthermore, as platelet function 
tests are not always routinely performed, the platelet 
defect may be overlooked in patients with mild 
bleeding manifestations, leading to failure to identify 
affected individuals. Recently, decreased 
megakaryocyte maturation and polyploidization and 
impaired proplatelet formation have been found to 
underlie the defect in platelet production (Bluteau et 
al., 2012), while platelet dysfunction has been 
attributed to both platelet storage pool deficiency 
(Gerard et al., 1991) and impaired αIIbβ3 integrin 
activation (Sun et al., 2004). Several RUNX1-targets 
have been proposed to be responsible for the platelet 
defects, including the Mpl receptor (Heller et al., 
2005), myosin 9 and myosin 10 (Bluteau et al., 2012), 
myosin regulatory light chain 9 (Sun et al., 2007), 
arachidonate 12-lipoxygenase and PKCθ (Sun et al., 
2004), although other genes are probably involved. 
Neoplastic risk 
Patients with FPD/AML are predisposed to myeloid 
malignancies, including AML, MDS and mixed 
myeloproliferative (MPN)/MDS syndromes. Several 
AML FAB subtypes have been reported to occur, 
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including M1, M2, M4 and M5, while refractory 
anemia with excess blasts, chronic myelomonocytic 
leukemia and hypoplastic MDS with myelofibrosis 
have been described among the cases with MDS and 
MPN/MDS. Patients may present with full-blown 
leukemia or develop leukemic transformation 
preceded by MDS. Although most hematological 
neoplasms involve the myeloid lineage, development 
of T-cell acute lymphoblastic leukemia has also been 
reported in rare cases (Preudhomme et al., 2009; 
Nishimoto et al., 2011). The rate of myeloid 
malignancies ranges between 20 to 65%. Median age 
at leukemia onset is 37 years old, ranging from 6 to 
75, indicating a variable latency period. Germline 
RUNX1 mutations seem to be insufficient by 
themselves for leukemia development and acquisition 
of additional cooperating events is required. A second 
event involving RUNX1 (somatic mutation or 
trisomy 21) often occurs at leukemia progression 
(Preudhomme et al., 2009) and several cytogenetic 
abnormalities have also been identified at this stage, 
including del(5q), -7/del(7q), +8, del(11q), 11q23 
rearrangements, del (20q). 
The mechanisms by which germline RUNX1 
mutations predispose to leukemia are beginning to be 
unraveled. RUNX1 deficiency in adult mice (RUNX1 
+/- and -/-) leads to an increase in committed myeloid 
progenitors, which could be explained by alteration in 
proliferative and/or self-renewal capacity or block in 
myeloid differentiation. In human, down-regulation 
of RUNX1-target NR4A3 has been shown by gene 
profiling of FPD/AML patient samples, associated to 
increased clonogenic potential of immature 
progenitors (Bluteau et al., 2011). Similarly to mouse 
models, this would lead to an expanded pool of 
multipotent and committed progenitors prone to 
secondary mutations, providing an explanation for 
leukemia predisposition in this disorder. Besides, 
there is evidence that RUNX1 functions as a tumor 
suppressor gene through up-regulation of p14ARF 
(Linggi et al., 2002), which enhances p53 activity by 
binding to its negative regulator Mdm3. 
Treatment 
Guidelines for management of FPD/AML patients are 
lacking due to the low frequency of this disorder and 
need to be assessed individually. Bleeding should be 
managed as for other platelet function disorders, 
according to the severity of bleeding manifestations. 
Patients with FPD/AML who develop AML or MDS 
are candidates for hematopoietic stem cell 
transplantation. As thrombocytopenia in FPD/AML is 
frequently mild or moderate and may be overlooked, 
mutational screening of potential sibling donors is 
required to avoid transplantation of stem cells 
harbouring the same RUNX1 mutation. 
Prognosis 
Prognosis depends on disease transformation to 
MDS/AML, the risk of which seems to vary 
according to the type of RUNX1 mutation and its 
effect on RUNX1 function. Data on the outcome of 
FPD/AML-associated MDS/AML is limited and may 
vary according to the type of malignancy. Similarly, 
outcome of HSC transplantation in FPD/AML is 
currently poorly defined, although increased graft 
failure or delayed engraftment and EBV-associated 
lymphoproliferative disorder have been described. 







Exons 3 to 5 of the RUNX1 gene encode the DNA-
binding runt homology domain, while the 
transactivation domain is enclosed in exons 7b and 8. 
RUNX1 is characterized by several isoforms, which 
are generated by alternative splicing and different 
promoter usage (Levanon et al., 2001; Miyoshi et al., 
1995). Most abundant species include isoforms 
RUNX1b and RUNX1c, which encode the full-length 
protein. 
Transcription 
Transcription of RUNX1c is initiated at the distal 
promoter and includes exons 1 and 2, while RUNX1b 
is regulated by the proximal promoter and starts at 
exon 3, both including exons 4, 5, 6, 7b and 8, 
according to nomenclature described by Miyoshi and 
colleagues. Thus, RUNX1b and c differ at their 
amino (N)-terminal end, being the former 27 amino 
acids shorter than the latter, although there appears to 
be no relevant functional differences between them. 
In contrast, the shorter RUNX1a isoform is a 
truncated variant spanning exons 3 to 7a with DNA-
binding but no transactivation activity which may 
potentially interfere with RUNX1b and c function, 
acting as a negative regulator. 
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Figure 1. Diagram of the RUNX1 gene and the three major mRNA and protein species, according to the nomenclature 
described by Miyoshi et al. Exons are represented by boxes, solid boxes indicate coding regions, while open boxes represent 
untranslated regions. RUNX1a differs from RUNX1b and RUNX1c at the C-terminal half of the protein, while RUNX1c differs at the N-




The RUNX1b protein consists of 453 amino acids 
with 48 kDa molecular weight, RUNX1c comprises 
480 amino acids while RUNX1a is formed by 250 
amino acids. RUNX1 belongs to a family of 
heterodimeric transcription factors which include 
RUNX2 and RUNX3, all of them forming 
heterodimers with CBFβ. RUNX factors comprise an 
N-terminal region named the runt homology domain 
(RHD), because of its homology to Drosophila Runt 
protein, which mediates both DNA binding and 
heterodimerization with CBFβ, and a carboxyl(C)-
terminal region responsible for transcriptional 
regulation (Ito et al., 1999). Heterodimerization with 
CBFβ enhances its DNA-binding capacity and 
protects it from proteolytic degradation.  
RUNX1 binds to the DNA consensus sequence 
TGTGGT and functions as a transcriptional activator 
or repressor, depending on promoter structure, the 
spliced variant expressed and the cellular context.  
RUNX1 is believed to act as a transcriptional 
organizer, recruiting other lineage-specific 
transcription factors to their promoters. 
Expression 
During embryogenesis, RUNX1 can be detected in 
hematopoietic stem cells and endothelial cells of the 
AGM region, while after organogenesis, RUNX1 is 
predominantly expressed in the hematopoietic 
system. Highest levels are found in thymus, bone 




The RUNX1/CBFβ transcription complex is critical 
for establishment of definitive hematopoiesis, as 
revealed in RUNX1-null mice, which die during 
embryonic development due to extensive bleeding. At 
this stage, RUNX1 expression at the level of the 
hemogenic endothelium is critical for endothelial to 
hematopoietic transition (Link et al., 2010).  
Despite its role in the establishment of definitive 
hematopoiesis, RUNX1 seems dispensable for the 
maintenance of adult hematopoietic stem cells, where 
it may have only a minor impact in their self-renewal 
capacity.  
However, this transcription factor is critical for the 
development of the megakaryocytic and lymphoid 
lineages.  
The role of RUNX1 in megakaryocyte biology has 
now been unveiled. Previous studies using cell lines 
suggested that RUNX1 participates in megakaryocyte 
lineage commitment and divergence from the 
erythroid pathway (Elagib et al., 2003), while 
heterozygous or conditional biallelic deletion of 
RUNX1 in mice leads to increased megakaryocyte 
growth with a partial arrest in polyploidyzation 
(Ichikawa et al., 2004).  
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Figure 2. Schematic structure of RUNX1 protein and position of germline mutations identified in thirty-six FPD/AML 
pedigrees. Missense mutations are shown in green dotted lines, frameshift mutations are represented by blue dashed lines, while 
nonsense mutations are shown in red. Intragenic deletion and duplication were identified in three and one pedigree each, 
respectively. Numbers in parentheses indicate mutations identified in more than one pedigree. 
 
More recent studies performed in FPD/AML patient 
samples and RUNX1 knock-down in primary 
megakaryocytes show that RUNX1 is involved in 
megakaryocyte differentiation, maturation, 
polyploidization and proplatelet formation, indicating 
that this transcription factor regulates platelet 
production by acting at both early and late stages of 
this process (Bluteau et al., 2012). Besides, RUNX1 
is essential for both T- and B-cell development, as 
revealed by the presence of several abnormalities in 
the lymphoid lineage in RUNX1-deficient mouse 
models, including a reduction in the numbers of CD4- 
and CD8-positive T cells, reduced CD4/CD8 ratio 
and defective T-cell proliferative response to TCR 
stimulation (Ichikawa et al., 2004; Wong et al., 
2011).  
More recently, RUNX1 was shown to be 
indispensable for Treg-cell function, implying a role 
for RUNX1 in autoimmune suppression (Wong et al., 
2011).  
In contrast, although RUNX1 deletion in mouse 
models leads to increased monocyte versus 
granulocyte progenitors, RUNX1 has no apparent 
effects in mature monocyte or granulocyte number or 
function (Guo et al., 2012).  
Known targets of RUNX1 in hematopoietic cells 
include cytokines, cell receptors and differentiation 
molecules, such as GM-CSF, IL-3, myeloperoxidase, 
neutrophil elastase, M-CSF and TCR receptors, as 
well as transcription factors, including CEBPA, PU.1, 
Gfi1 and Gfi1b. 
 
Homology 
Other members of the RUNX family include RUNX2 
and RUNX3, which are alternative heterodimeric 
parterns for CBFβ. 
Mutations 
Germinal 
Linkage to chromosome 21q22.12 was established in 
1996 in a large FPD/AML pedigree described by 
Dowton and colleagues (Dowton et al., 1985). 
Among genes mapping to this region, RUNX1 
emerged as an attractive candidate for this disorder 
and subsequently, RUNX1 mutations were identified 
in several FPD/AML patients (Song et al., 1999). 
Twenty-seven different mutations located in exons 3 
to 8 have been detected in thirty-six pedigrees 
reported so far, including missense, nonsense and 
frameshift mutations (Liew and Owen, 2011). In 
addition, whole or partial hemizygous RUNX1 
deletion (Song et al., 1999; Beri-Dexheimer et al., 
2008; Preudhomme et al., 2009) and intragenic gene 
duplication (Jongmans et al., 2010) have also been 
described. These latter defects may be missed by 
conventional sequencing and further genetic analysis 
assessing gene copy number, such as SNP genotyping 
array or array-comparative genomic hybridization 
(CGH) may be required for diagnosis. Besides,  
syndromic constitutional microdeletions in 21q22 
encompassing the RUNX1 locus have been reported 
to cause congenital sporadic thrombocytopenia and 
MDS/AML predisposition associated to a complex  
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phenotype characterized by mental retardation, 
developmental delay, dysmorphic features and 
several birth defects (Shinawi et al., 2008). 
Most RUNX1 mutations are clustered within the 
RHD (exons 3 to 5), although mutations in the C-
terminal region have been detected in one fourth of 
the patients. In vitro functional studies have shown 
that RHD mutations abrogate the DNA-binding and 
transactivation capacity while, according to whether 
they retain or loose their ability to heterodimerize 
with CBFβ, they interfere with the wild-type protein 
in a dominant-negative manner or act through 
haploinsufficiency, respectively. On the other hand, 
C-terminal mutants have an enhanced capacity to 
bind DNA, due to lack of a DNA-binding inhibitory 
domain, and interact strongly with CBFβ and are 
therefore expected to strongly repress the wild-type 
allele. It has been suggested that dominant-negative 
mutations cause higher predisposition to leukemia 
than those acting via haploinsufficiency, although this 
observation needs to be confirmed in larger number 
of patients (Michaud et al., 2002). 
Somatic 
RUNX1 is one of the genes most frequently 
dysregulated in leukemia, mostly through 
chromosomal translocations, mutations and 
amplifications (Mangan and Speck, 2011). RUNX1 
was originally cloned as the target of the t(8;21) 
chromosomal translocation characteristic of AML 
FAB subtype M2, which encodes the RUNX1 
(AML1)-ETO fusion product, and was subsequently 
found to be involved in other chromosomal 
translocations in both myeloid and lymphoblastic 
neoplasms, such as t(3;21) and t(12;21), which 
generate RUNX1-MDS1/EVI1 and TEL-RUNX1 
transcripts, respectively. Besides, acquired point 
mutations in the RUNX1 gene have been reported in 
5% sporadic leukemia, predominantly in FAB 
subtype M0, where they are frequently biallelic. 
Moreover, mutations have been detected in 
approximately 8% MDS and chronic 
myelomonocytic leukemia patients and 28% 
secondary AML following MDS. While AML 
mutations occur mainly in the RHD, both N-terminal 
and C-terminal mutations have been reported in 
MDS. On the other hand, RUNX1 amplification 
occurs predominantly in pediatric ALL. 
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